Bo Li


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Bo Li handles adversarial matters, with a focus on securities litigation, regulatory investigation and compliance, and international arbitration. Bo represents clients from a broad range of industries and provides them with client-oriented, proactive, and cost-effective services. Bo also devotes significant time to pro bono work including representing clients in immigration matters and serving as judge for various prestigious moot court competitions.

Prior to joining O’Melveny, Bo interned with the International Criminal Court in The Hague.


  • Mandarin Chinese
  • English


Bar Admissions

  • New York


  • University of Virginia School of Law, LL.M.
  • China University of Political Science and Law, China-EU School of Law, LL.M., European and International Law and Human Rights Law; Theses: (1) The Theory and Practice of Chinese Bilateral Investment Treaties (English), (2) Self-Determination and Territorial Integrity in the Post-Colonial Era (Chinese)
  • Southwestern University of Finance and Economics, LL.B.: with honors

Professional Activities

Bar Exam

  • Passed Chinese Bar Exam


  • “A Comparative View of Pretrial Evidence and Disclosure in Aid of Foreign Main Proceedings”, 2nd Fraud, Asset Tracing and Recovery, Hong Kong, June 6, 2016
  • “The Role of Law in China’s Economic Growth”, 7th Seminar for European Diplomats, hosted by Ministry of Foreign Affairs of the PRC, Beijing, June 20, 2012


  • Criminal Procedure Stories: Challenges in Constitutional Criminal Procedure, Past Present and Future, Carol S. Steiker, Renmin University Press, March 2012 


  • “Faith in Procedural Justice - Chinese Perspective”, Legal System and Society, July 2008


  • Representing a Chinese multinational technology company in a security class action
  • Representing a Chinese conglomerate and a leading information technology company in the Supreme Court of the State of New York
  • Advised a U.S. publicly traded Chinese agriculture company on its securities class action
  • Represented a public traded entertainment company in an HKIAC arbitration seated in Hong Kong involving a multimillion dollar claim
  • Represented a Chinese real estate group in a US$35 million HKIAC arbitration in relation to disputes arising from alleged breaches of a Master Investment and Shareholder’s Agreement
  • Advised a high net worth individual on a multi-million dollar contractual dispute before Chinese court
  • Advised a US publicly traded company on trade secret infringement matters, including investigation and negotiation
  • Advised several multinational companies on various commercial and civil litigation matters in Chinese courts 
  • Advised a U.S. publicly traded company on its trade secret matters 
  • Advised companies in a variety of sectors on Chinese law matters in international commercial arbitrations


  • Represented a leading network company to conduct investigation in response to the DOJ’s criminal probes
  • Conducted an internal investigation for a global supplier of semiconductors
  • Conducted an internal investigation, from document collection and review, individual interview, to final report preparation, for a multinational pharmaceutical company with respect to FCPA and anti-corruption compliance
  • Conducted an internal investigation including extensive document review and interviews for a multinational real estate company with respect to FCPA and anti-corruption compliance
  • Advised a leading multinational medical device company in an internal investigation with respect to FCPA and Chinese anti-corruption law issues
  • Advised a Fortune 500 company’s audit committee in an internal investigation regarding anti-corruption compliance of its Chinese subsidiary
  • Advised management team of a US publicly traded Chinese company in an internal investigation with respect to FCPA issues in China
  • Advised a US medical technologies and services provider with FCPA issues in China
  • Advised a global investment bank in its FCPA and compliance-related internal investigation regarding government relationship activities
  • Advised a US electronics manufacturer in an FCPA-related internal investigation project
  • Advised a US publicly traded Chinese company for its compliance program review and revamp
  • Provided anti-corruption training to a world leading investment firm


  • Represented the PKU-VMing buyer consortium in a competing going private bid against management for a Chinese biopharmaceutical company Sinovac Biotech Ltd.
  • Represented Phoenix Healthcare (01515.HK) on its US$220 million IPO and listing on the Hong Kong Stock Exchange
  • Represented Goldman Sachs and Credit Suisse as joint bookrunners in the US$137.7 million initial public offering of Tarena International (Nasdaq: TEDU), a leading provider of professional education services in China
  • Represented China Eastern Airlines in connection with its “dim sum” bond offering of RMB2.2 billion 3.875% guaranteed bonds
  • Represented a leading Chinese e-commerce company in its investment of a mobile gaming company
  • Advised a leading solar panel producer on its debt restructuring
  • Represented a leading online education provider on its follow-on offering
  • Advised a leading testing service company on its corporate and securities compliance matters